Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Biochemical and Biophysical Research Communications|March 30, 2004
Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapyNaoki Okada, Jian-Qing Gao, Akinori Sasaki, et al.
British Journal of Pharmacology|February 4, 2012
Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRPHiroyuki Kusuhara, Hidetoshi Furuie, Akihiro Inano, et al.
ADMET & DMPK|March 30, 2022
Harmonizing solubility measurement to lower inter-laboratory variance - progress of consortium of biopharmaceutical tools (CoBiTo) in JapanAsami Ono, Naoya Matsumura, Takahiro Kimoto, et al.
Pharmaceutical Research|February 16, 2022
Prediction of Oral Drug Absorption in Rats from In Vitro DataYoshiyuki Akiyama, Naoya Matsumura, Asami Ono, et al.
Pharmaceutical Research|December 16, 2025
Intracerebral Distribution of Drugs with Diverse Blood-brain Barrier Transport Characteristics: In vivo Analysis using Brain Microdialysis in Cynomolgus MonkeysTakuya Fujita, Yukari Kamikozawa, Makoto Ozawa, et al.
Journal of Pharmaceutical Sciences|December 22, 2019
Prediction Characteristics of Oral Absorption Simulation Software Evaluated Using Structurally Diverse Low-Solubility DrugsNaoya Matsumura, Shun Hayashi, Yoshiyuki Akiyama, et al.
Journal of Medicinal Chemistry|March 19, 2024
Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) AgonistsKenneth L Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, et al.
Journal of Medicinal Chemistry|March 19, 2024
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart FailureKenneth L Granberg, Shigeki Sakamaki, Niklas Larsson, et al.
The Journal of Biological Chemistry|November 16, 2007
Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonistHiroko Shibata, Yasuo Yoshioka, Akiko Ohkawa, et al.
Pageof 15